Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 20/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19224598 | 0.93 | RIPK1 (0.57) | RIPK1 | |
| SCHEMBL29415797 | 0.93 | RIPK1 (0.57) | RIPK1 | |
| SCHEMBL19224601 | 0.93 | RIPK1 (0.57) | RIPK1 | |
| SCHEMBL21496580 | 0.81 | RIPK1 (0.49) | RIPK1 | |
| SCHEMBL1561640 | 0.78 | MME (0.43) | RIPK1 | |
| SCHEMBL19207716 | 0.78 | RIPK1 (0.64) | RIPK1 | |
| SCHEMBL19224695 | 0.78 | RIPK1 (0.56) | RIPK1 | |
| SCHEMBL19228506 | 0.77 | RIPK1 (0.53) | RIPK1 | |
| SCHEMBL29415677 | 0.77 | RIPK1 (0.53) | RIPK1 | |
| SCHEMBL31249665 | 0.77 | RIPK1 (0.53) | RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388601-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2025-12-25 | — | — | US | disclosed |
| US-12358928-B2 | Compounds, compositions and methods | DENALI THERAPEUTICS INC. (US) | 2025-07-15 | — | — | US | disclosed |
| US-20240150376-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2024-05-09 | — | — | US | disclosed |
| US-20230043400-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2023-02-09 | — | — | US | disclosed |
| EP-3414239-A2 | INHIBITORS OF RECEPTOR-INTERACTING PROTEIN KINASE 1 | Denali Therapeutics Inc. (US) | 2018-12-19 | — | — | EP | disclosed |
| WO-2017136727-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. (US) | 2017-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388601-A1 | Compounds, Compositions and Methods | AURKC, WEE2, ERBB2 | RIPK1 1507/4885 |
| US-20240150376-A1 | Compounds, Compositions and Methods | PIK3CA, PLK1, PIK3CB | RIPK1 416/4885 |
| US-12358928-B2 | Compounds, compositions and methods | PIK3CA, PLK1, PIK3CB | RIPK1 416/4885 |
| US-20230043400-A1 | Compounds, Compositions and Methods | PIK3CA, PLK1, PIK3CB | RIPK1 416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.